Press Releases

SOUTH PLAINFIELD, N.J. , Sept. 13, 2018 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at Jefferies Gene Therapy Summit on Thursday, September 27 th at 1:30 p.m. EST . The presentation will be webcast live on the Events and

- Awards Program Recognizes Excellence and Innovation in the Duchenne Muscular Dystrophy Community - SOUTH PLAINFIELD, N.J. , Sept. 7, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) is pleased to announce the recipients of the Company's 2018 global STRIVE Awards (Strategies to Realize

SOUTH PLAINFIELD, N.J. , Aug. 24, 2018 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on August 22 , 2018 it approved non-statutory stock options to purchase an aggregate of 381,500 shares of its common stock to 15 new employees.

SOUTH PLAINFIELD, N.J. , Aug. 23, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that it has successfully completed the acquisition of Agilis Biotherapeutics, Inc. , a private biotechnology company focused on the advancement of innovative gene therapy programs for rare

SOUTH PLAINFIELD, N.J. , Aug. 10, 2018 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on August 6 , 2018 it approved non-statutory stock options to purchase an aggregate of 170,200 shares of its common stock to 27 new employees.

Entered into agreement to acquire Agilis Biotherapeutics In-licensed LATAM commercial rights to Tegsedi™ (inotersen) and Waylivra™ (volanesorsen) EC approval of Translarna™ label expansion to children as young as 2 years of age Compelling data from FIREFISH study SOUTH PLAINFIELD, N.J. , Aug.

- PTC in-licenses regional rights to TEGSEDI™ and WAYLIVRA™ from Akcea - SOUTH PLAINFIELD, N.J. and CAMBRIDGE, Mass. , Aug. 2, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), and Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc.

SOUTH PLAINFIELD, N.J. , July 26, 2018 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2018 financial results and provide an update on the company's business and outlook on Tuesday, August 7,

- Post hoc analysis of the placebo arm of ACT DMD Data Published in Muscle & Nerve - SOUTH PLAINFIELD, N.J. , July 24, 2018 /PRNewswire/ --   PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the publication of data in Muscle & Nerve comparing the efficacy and safety of deflazacort and

- Expands and diversifies current pipeline with four gene therapy programs - - BLA submission in AADC deficiency expected in 2019 - SOUTH PLAINFIELD, N.J. , July 19, 2018 /PRNewswire/ --   PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has entered into an agreement to acquire Agilis